Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer.
Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer.
Oncologist. 2018 Apr 12;:
Authors: Chu CY, Choi J, Eaby-Sandy B, Langer CJ, Lacouture ME
Abstract
Dermatologic adverse events (dAEs) are common with the use of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy. First- and second-generation agents (erlotinib, gefitinib, and afatinib) are frequently associated with acneiform rash, pruritus, xerosis, and paronychia; the incidence and characterization of these dAEs have been well described. However, there is evidence that the dAE profile is different with third-generation EGFR-TKIs. Herein, we describe the dAEs associated with third-generation EGFR-TKIs and our clinical experience with osimertinib, a third-generation EGFR-TKI approved by the U.S. Food and Drug Administration for the treatment of metastatic, EGFR T790M mutation-positive non-small cell lung cancer in patients whose disease has progressed on or after EGFR-TKI therapy. Case summaries of patients from two of our institutions who received osimertinib and were referred to a dermatologist for dAEs are also presented. Overall, the evidence suggests that osimertinib is associated with less severe and less frequent dAEs than first- and second-generation EGFR-TKIs and that therefore a different approach is warranted. Finally, we outline dAE management approaches for osimertinib in the context of those typically employed ...
Source: The Oncologist - Category: Cancer & Oncology Authors: Chu CY, Choi J, Eaby-Sandy B, Langer CJ, Lacouture ME Tags: Oncologist Source Type: research
More News: Cancer | Cancer & Oncology | Dermatology | Food and Drug Administration (FDA) | Health Management | Lung Cancer | Non-Small Cell Lung Cancer | Skin | Tarceva